Cure8 research brief
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of 12-week treatment response in IBD.
Clinicians treating IBD, researchers in IBD biomarkers and microRNA biology, and adult patients interested in personalized medicine approaches.
This study measured circulating microRNA-145 (miR-145) and microRNA-191 (miR-191) in plasma from adults with Crohn’s disease and ulcerative colitis and compared levels to healthy controls.
It reports that active IBD was associated with lower miR-145 and higher miR-191, and that higher baseline miR-145 and lower miR-191 were associated with clinical response at 12 weeks (CDAI for CD, Mayo score for UC). The analysis used qRT‑PCR on plasma samples and retrospective clinical data from 183 IBD patients and 92 healthy controls.
The authors present correlations with disease-activity scores and inflammatory markers and report ROC analyses suggesting discriminative ability. This article is an observational clinical study reporting potential non-invasive biomarkers; it does not by itself establish that measuring these miRNAs should change clinical care.
Further validation in independent, prospective cohorts and standardized assays would be needed before routine clinical use.
Findings are from a retrospective observational cohort reported in the article abstract; they are promising but need independent prospective validation and standardized laboratory methods before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
